Sarepta stock jumps on FDA nod for ELEVIDYS gene therapy

February 16, 2024 7:46 AM EST Send to a Friend
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has seen its stock price surge by more than 11% in premarket trading after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login